Hims and Ro Stopped Selling Compounded GLP-1. Here's What Your Options Actually Are.

If you opened an email from Hims this spring suggesting you transition to brand-name Wegovy at around $499 a month, or off the platform entirely, you are not alone. Hims & Hers, Ro, and Calibrate — three of the largest compounded-GLP-1 telehealth platforms of 2024 and 2025 — have all stopped selling compounded semaglutide and most are phasing out compounded tirzepatide. The shift is not subtle, and tens of thousands of patients are working through what to do next.

This is a patient-education piece, not a marketing pitch. The goal is to explain what actually happened in regulatory and industry terms, lay out the four real options open to a patient transitioning off Hims or Ro compounded GLP-1, and walk through the questions to ask any new provider in the post-crackdown environment.

What Happened: The Hims/Ro/Calibrate Compounded GLP-1 Exit

In January 2026, Hims & Hers announced a partnership with Novo Nordisk to distribute brand-name Wegovy through the Hims platform at approximately $499 per month, and as part of that deal, agreed to stop advertising compounded GLP-1 products. Reporting from Barchart and multiple industry analyses have called this "a new era for compounded GLP-1 drugs." Ro followed with a similar pivot in early 2026, distributing brand-name Wegovy and Zepbound and discontinuing its compounded program. Calibrate moved to brand-name only.

Then in May 2026, the FDA proposed adding semaglutide, tirzepatide, and liraglutide to its 503B "Difficult to Compound" list. Several outsourcing facilities — including ProRx, BPI Labs, and Medisource (which had been Hims's compounding partner) — either ceased GLP-1 production or scaled back significantly. Partnership for Safe Medicines documented the timeline in detail.

For patients, the practical result has been transition notices throughout April and May 2026 with options including switching to brand Wegovy through the new Novo-Hims partnership, switching to oral weight-loss alternatives on the same platform, or ending therapy.

Why It Happened: FDA's 2026 Enforcement Push

The shift was not the result of a single FDA decision. It was a sequence of regulatory actions across 2025 and 2026 that progressively narrowed the legal pathway for mass-marketed compounded GLP-1 telehealth:

• February 2025: FDA declared the semaglutide shortage officially resolved, ending the temporary 503B pathway that allowed bulk compounding "essentially as copies" of the brand-name drug.
• October 2024: Tirzepatide came off the shortage list under similar reasoning.
• February 2026: FDA issued 30 warning letters to telehealth companies and compounding pharmacies for "false or misleading" marketing of compounded semaglutide and tirzepatide, citing claims that compounded products were "FDA-approved," "identical to Ozempic," or "safer than the brand."
• April 2026: FDA sent warnings directly to 503B outsourcing facilities. Many scaled back or exited GLP-1 production.
• May 2026: FDA proposed restricting semaglutide, tirzepatide, and liraglutide from the 503B bulks list, stating there is "no longer a justification for large-scale compounding."

Industry counsel including Frier Levitt have noted that this is the regulatory equivalent of pulling the rug from the mass-market compounded GLP-1 business model. FDA itself has separately documented its concerns about unapproved GLP-1 drugs used for weight loss.

Your Four Real Options Now (With the Math)

Here is the honest landscape of what's available to a patient transitioning off a Hims, Ro, or Calibrate compounded GLP-1 program in May 2026.

The brand-name options through manufacturer cash-pay programs have come down substantially from 2024 levels (where Wegovy and Zepbound retail was approximately $1,000–$1,400 per month). At the same time, 503A patient-specific compounded programs — where they remain legally available with documented clinical need — are typically lower-cost.

The right answer for any individual patient is a clinical decision made with a prescribing physician, based on health history, insurance coverage, side-effect tolerance, and personal financial picture.

Tirzepatide or Semaglutide: How to Think About the Choice

Many patients transitioning off Hims compounded GLP-1 were on semaglutide because that was Hims's lead product. The natural question for the next step is: stay on semaglutide, or switch to tirzepatide?

What the clinical evidence shows

Tirzepatide is a dual GIP/GLP-1 receptor agonist (the molecule used in FDA-approved Mounjaro and Zepbound from Eli Lilly). Semaglutide is a GLP-1 receptor agonist (the molecule used in FDA-approved Ozempic and Wegovy from Novo Nordisk). Compounded preparations of either molecule are not FDA-approved, and FDA does not review compounded drugs for safety, effectiveness, or quality before marketing.

In a 2025 head-to-head trial published in the New England Journal of Medicine, tirzepatide produced approximately 20.2% average weight loss compared with 13.7% for semaglutide at comparable doses — nearly 50% more effective on the primary outcome. In our experience, many patients also report tolerable side-effect profiles on tirzepatide. The clinical question of which is right for any specific patient depends on health history and is a conversation for the prescribing physician.

If you specifically want to stay on semaglutide

Continuity matters. Some patients have been on semaglutide for months or years, have established their tolerance, and prefer not to switch molecules. That is a legitimate clinical preference. SkinnyVIP can prescribe compounded semaglutide where the prescribing physician determines it is the appropriate clinical choice for the individual patient, under the 503A patient-specific compounding pathway.

What 503A Means and Why It Matters in the New Environment

This is the most important regulatory distinction for patients trying to navigate the post-2026 environment. There are two compounding pathways under federal law:

• 503A patient-specific compounding. A licensed physician writes a prescription for an individual patient based on documented clinical need (allergy to brand-name inactive ingredients, a dose not commercially available, specific titration requirements). The prescription is filled by a licensed compounding pharmacy. This pathway remains legal in 2026.
• 503B bulk outsourcing. An outsourcing facility produces compounded drugs in bulk for hospitals and clinics, typically only for drugs on the FDA shortage list or with documented clinical justification. This pathway is what FDA's May 2026 action is restricting for semaglutide, tirzepatide, and liraglutide.

Hims, Ro, and Calibrate relied substantially on 503B bulk outsourcing to support their high-volume compounded programs at flat consumer rates. When the 503B pathway closed for GLP-1s, their entire model became commercially unworkable.

Telehealth practices that operate within the 503A patient-specific pathway, where each prescription is supported by documented clinical justification, continue to operate within the current legal framework. SkinnyVIP is one such practice.

Where SkinnyVIP Fits

SkinnyVIP is a telemedicine practice that prescribes compounded tirzepatide and compounded semaglutide for individual patients under the 503A patient-specific compounding pathway. The medical exam, prescription, and pharmacy fulfillment are managed by a licensed clinical platform that supports physician-supervised prescribing in all 50 states. Compounded medications are not FDA-approved, and FDA does not review compounded drugs for safety, effectiveness, or quality before marketing.

What is structurally different about SkinnyVIP from the Hims and Ro model:

• No membership fee. The price you see is the entire price. No separate platform fee, no separate "medical access" fee, no $149 mandatory monthly add-on.
• No contract. No auto-renewal. No retention specialist phone calls to cancel. You pay once for a three-month treatment cycle and actively decide whether to start a new one.
• One transparent price for any dose. $695 for a 3-month plan (about $232 per month effective) covers any dose your physician prescribes — from a starter dose of 2.5 mg per week through a maintenance dose of up to 15 mg per week. Medication, physician consultation, follow-up check-ins, and shipping are all included. The price stays the same when your dose changes.
• Physician-supervised, patient-specific prescribing. A licensed physician conducts the medical exam, reviews your health history, and writes a prescription based on your individual clinical situation.

For full pricing and clinical details, see the SkinnyVIP pricing page and the dedicated tirzepatide page.

Your 7-Question Provider Transition Checklist

Whether you're considering SkinnyVIP, another 503A telehealth practice, or one of the brand-name options, run this checklist before you commit to any new provider in 2026. Get the answers in writing.

Bottom Line

The compounded GLP-1 telehealth landscape that defined 2024 and 2025 has changed substantially. Mass-market 503B compounded programs at flat consumer rates are largely closing. Brand-name manufacturer cash-pay programs have closed much of the price gap. Patient-specific 503A compounded pathways remain legal but require clinical documentation and licensed-physician prescribing.

If you were on a Hims, Ro, or Calibrate compounded GLP-1 program and your supply is ending, the practical step is to identify your next-step provider before your current supply runs out. That might be brand-name through the new Hims-Novo partnership at around $499 per month. It might be brand-name through Novo Nordisk NovoCare or LillyDirect directly. It might be a 503A telehealth practice with physician-supervised patient-specific compounding, like SkinnyVIP. It might be a non-GLP-1 approach with your doctor.

What it should not be is a panic transition to whatever provider has the loudest paid ad, or a stockpile from an unverified source, or a pause in therapy that you regret three months later. Whatever path you choose, ask the seven questions above, get the answers in writing, and let the physician make the clinical decision.